reports
- Jonathan Moreland
XPL SOLITARIO ZINC
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
TTSH TILE SHOP HOLDINGS INC.
STAA STAAR SURGICAL CO.
SIG SIGNET JEWELERS LIMITED
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
RGP RESOURCES CONNECTION INC.
PBPB POTBELLY CORP.
PBF PBF ENERGY INC. CLASS A
CVGW CALAVO GROWERS INC.
CRMD CORMEDIX INC.
CRM SALESFORCE.COM INC.
CMC COMMERCIAL METALS COMPANY
CDXS CODEXIS
APA.. APA CORP.
AB ALLIANCEBERNSTEIN HOLDING L.P.
FLWS 1-800-FLOWERS.COM CL A
GWRS GLOBAL WATER RESOURCES
JELD JELD-WEN HOLDING INC.
SVRA SAVARA
WGO WINNEBAGO INDUSTRIES INC.
PNBK PATRIOT NATIONAL BANCORP
FF FIRST MINING GOLD
DOMO DOMO INCORPORATED
FUND ROYCE FOCUS TRUST
FGBI INC.
VEL FIRST GUARANTY BANCSHARES
ZYME VELOCITY COMPOSITES
RZLT ZYMEWORKS INC.
WOOF REZOLUTE
UAN INC.
VSCO PETCO HEALTH AND WELLNESS
BTMD CVR PARTNERS LP
EWTX VICTORIA'S SECRET & CO
TEAF HAYMAKER ACQUISITION CORP III
JMSB EDGEWISE THERAPEUTICS INC
ERNA ECOFIN SUSTAINABLE AND SOCIAL IMPACT TERM FUND
GTE JOHN MARSHALL BANCORP INC
SSII ETERNA THERAPEUTICS INC.
CATX GRAN TIERRA ENERGY INC.
ADVM SS INNOVATIONS INTERNATIONAL INC
SUNS PERSPECTIVE THERAPEUTICS
BNTC INC.
FG ADVERUM BIOTECHNOLOGIES INC.
ALMU SUNRISE REALTY TRUST
FTLF BENITEC BIOPHARMA INC
ECF F AND G ANNUITIES AND LIFE
INC.
AELUMA
INC.
FITLIFE BRANDS INC.
ELLSWORTH FUND LTD
Savara Inc: 1 director
A director at Savara Inc bought 150,000 shares at 2.775USD and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
- Jonathan Moreland
OPK OPKO HEALTH INC.
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
SVRA SAVARA
PNBK PATRIOT NATIONAL BANCORP
FUND ROYCE FOCUS TRUST
WOOF INC.
UAN PETCO HEALTH AND WELLNESS
GAM CVR PARTNERS LP
CATX GENERAL DE ALQUILER DE MAQUINARIA
SUNS PERSPECTIVE THERAPEUTICS
AFCG INC.
SUNRISE REALTY TRUST
AFC GAMMA
INC.
Cannae Holdings, Inc. Responds to Carronade Capital and Affirms the Bo...
LAS VEGAS--(BUSINESS WIRE)-- Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or the “Company”) today issued a response to Carronade Capital’s recent statement and director nomination notice. The Company also highlighted the significant actions already taken to position the Company for long-term value creation. In February 2024, Cannae began taking decisive action, with a sharp eye towards improving and monetizing its investment holdings, returning capital to shareholders, and reducing operational expenses. These steps aim to grow the net asset value (“NAV”) of our portfolio and close Cannae’s sh...
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramo...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) International Conference taking place May 16-21, 2025, in San Francisco, CA. The Company will also host an Industry Theater titled “Advances in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)” at the meeting. ATS 2025 Posters Poster Title: Molgramostim Reduces Surfactant Burden and Number of Whole Lung Lavage Procedures in Patients with A...
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot T...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot (DBS) Test in the U.S., an evolution of the first serum-based assay the Company launched. The DBS test helps obtain a diagnosis of aPAP, a rare autoimmune lung disease caused by antibodies targeting GM-CSF, with only a finger-prick blood sample. The DBS test demonstrates a high correlation between GM-CSF autoantibody levels in dried serum and traditional serum samples, ensuring reliable res...
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement as required by Nasdaq Listing Rule 5550(b)(1). On February 26, 2025, Mustang received formal notice from Nasdaq confirming that the Company has satisfied the minimum stockholders’ equity requirem...
Savara Announces Participation in the Leerink Global Healthcare Confer...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will attend the Leerink Global Healthcare Conference and participate in a fireside chat on Tuesday, March 11th, 10:40am ET/7:40am PT. The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company’s corporate website at and will be archived for 90 days. Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our ...
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the exit of the lease for its manufacturing facility in Worcester, Massachusetts and concurrent divestment of certain fixed assets including furniture and equipment to AbbVie Bioresearch Center Inc., a Delaware corporation (“AbbVie”), ...
Cannae Holdings, Inc. Announces Fourth Quarter and Full Year 2024 Fina...
LAS VEGAS--(BUSINESS WIRE)-- Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or the “Company”) has released its fourth quarter and full year 2024 financial results by posting them to its website. Please visit the Cannae website at to view the fourth quarter and full year 2024 financial results, which are included in its Letter to Shareholders. Conference Call As previously announced, Cannae will host a conference call, today, February 24, 2025 at 5:00pm (Eastern Time), to discuss its fourth quarter and full year 2024 results. The conference call can be accessed by dialing 1-844-826-3035 (dom...
Cannae Holdings, Inc. Announces Quarterly Cash Dividend of $0.12
LAS VEGAS--(BUSINESS WIRE)-- Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or the “Company”) today announced that its Board of Directors has declared a quarterly cash dividend of $0.12 per share. The dividend will be payable March 31, 2025, to shareholders of record as of March 17, 2025. About Cannae Holdings, Inc. We primarily acquire interests in operating companies and are actively engaged in managing and operating a core group of those companies. We believe that our long-term ownership and active involvement in the management and operations of companies helps maximize the value of those b...
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On February 12, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 97,500 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 82,500 shares of the Company’s common stock. These equity a...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
SPKX, EGO, ASTL, IEX, MOD, CARR, KMT, TTC, DOOO, BWA, WNC, THRM, FOXF, GNTX, AOS, RRX, ADI, TXN, AMD, PI, SYNA, SWKS, IPGP, POWI, MCHP, DIOD, ON, FORM, AMKR, COHU, ITRI, LDOS, TXT, OLED, VECO, HOG, DHI, LEN, SPB, PII, CNR, hort Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical pattern...
SYNA SYNAPTICS INCORPORATED
ADI ANALOG DEVICES INC.
WNC WABASH NATIONAL CORPORATION
VECO VEECO INSTRUMENTS INC.
TXT TEXTRON INC.
TXN TEXAS INSTRUMENTS INCORPORATED
THRM GENTHERM INCORPORATED
RBC REGAL BELOIT CORP
POWI POWER INTEGRATIONS INC.
PII POLARIS INC.
ON ON SEMICONDUCTOR CORPORATION
OLED UNIVERSAL DISPLAY CORPORATION
MOD MODINE MANUFACTURING COMPANY
MCHP MICROCHIP TECHNOLOGY INCORPORATED
LEN LENNAR CORPORATION CLASS A
LDOS LEIDOS HOLDINGS INC.
ITRI ITRON INC.
IPGP IPG PHOTONICS CORPORATION
GNTX GENTEX CORPORATION
FOXF FOX FACTORY HOLDING CORP.
FORM FORMFACTOR INC.
DIOD DIODES INCORPORATED
BWA BORGWARNER INC.
CNR. CANADIAN NATIONAL RAILWAY COMPANY
DHI D.R. HORTON INC.
SWKS SKYWORKS SOLUTIONS INC.
DOO BRP INC.
COHU COHU INC.
KMT KENNAMETAL INC.
TTC TORO COMPANY
AOS A. O. SMITH CORPORATION
PI IMPINJ INC.
SPXX NUVEEN S&P 500 DYNAMIC OVERWRI
AMD ADVANCED MICRO DEVICES INC.
AMKR AMKOR TECHNOLOGY INC.
HOG HARLEY-DAVIDSON INC.
SPB SPECTRUM BRANDS HOLDINGS INC.
ELD ELDORADO GOLD CORPORATION
CARR CARRIER GLOBAL CORP.
ASTL LEGATO MERGER CORP
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requireme...
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement WORCESTER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing. In addition, as a result of the closing of the public offering announced by the Company on February 10, 2025, the Company believes that it has a minimum of $2.5 milli...
Cannae Holdings, Inc. Announces Fourth Quarter and Full Year 2024 Earn...
LAS VEGAS--(BUSINESS WIRE)-- Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or the “Company”) today announced that the Company will release its fourth quarter and full year 2024 financial results after the market close on Monday, February 24, 2025. The Company will also hold a conference call to discuss its financial results at 5:00 pm (Eastern Time) on the same day. The conference call can be accessed by dialing 1-844-826-3035 (domestic) or 1-412-317-5195 (international) and asking for the Cannae Holdings Fourth Quarter 2024 Earnings Call. A telephonic replay will be available at the conclusi...
Mustang Bio Announces Closing of $8 Million Public Offering
Mustang Bio Announces Closing of $8 Million Public Offering WORCESTER, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the closing of its previously announced public offering, for the issuance and sale of an aggregate of 2,657,807 shares of its common stock (or common stock equivalents in lieu thereof), Series C-1 warrants to purchase up to 2,657,807 sha...
Mustang Bio Announces Pricing of $8 Million Public Offering
Mustang Bio Announces Pricing of $8 Million Public Offering WORCESTER, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the pricing of a public offering of an aggregate of 2,657,807 shares of its common stock (or common stock equivalents in lieu thereof), Series C-1 warrants to purchase up to 2,657,807 shares of common stock and Series C-2 warrants to pur...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
ADI ANALOG DEVICES INC.
TXN TEXAS INSTRUMENTS INCORPORATED
SCCO SOUTHERN COPPER CORPORATION
POWI POWER INTEGRATIONS INC.
ON ON SEMICONDUCTOR CORPORATION
MOD MODINE MANUFACTURING COMPANY
MCHP MICROCHIP TECHNOLOGY INCORPORATED
LDOS LEIDOS HOLDINGS INC.
JJSF J & J SNACK FOODS CORP.
HSY HERSHEY COMPANY
GPRE GREEN PLAINS INC.
GGG GRACO INC.
GD GENERAL DYNAMICS CORPORATION
FORM FORMFACTOR INC.
FCX FREEPORT-MCMORAN INC.
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ASH ASHLAND GLOBAL HOLDINGS INC.
APOG APOGEE ENTERPRISES INC.
BCPC BALCHEM CORPORATION
TECK.B TECK RESOURCES LIMITED CLASS B
COHU COHU INC.
CRUS CIRRUS LOGIC INC.
ENTG ENTEGRIS INC.
FSLR FIRST SOLAR INC.
LMT LOCKHEED MARTIN CORPORATION
NX QUANEX BUILDING PRODUCTS CORPORATION
WFT.. WEATHERFORD INTERNATIONAL PLC
RDY DR. REDDY'S LABORATORIES LTD. ADS
PI IMPINJ INC.
BHP BHP GROUP
ICHR ICHOR HOLDINGS LTD.
RTP.. RIO TINTO PLC ADS (MEXICO)
AMD ADVANCED MICRO DEVICES INC.
ELD ELDORADO GOLD CORPORATION
CFB CROSSFIRST BANKSHARES
LHX L3HARRIS TECHNOLOGIES INC
HII. HORIZONS CDN INS
RVMD REVOLUTION MEDICINES
CARR CARRIER GLOBAL CORP.
UTZ UTZ BRANDS INC (A)
OTIS OTIS WORLDWIDE CORPORATION
FLNC FLUENCE ENERGY INC
STM STABILUS SE
ELVN IMARA INC
HEI HAWAIIAN ELECTRIC CO INC COM
AMKR 21SHARES MAKER ETP
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim In...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced a manuscript titled, was published online in the journal ERJ Open Research. The outcomes data presented suggest that treatment with molgramostim addresses the underlying pathophysiology of aPAP, resulting in improved lung function, decreased disease burden, restored patient functionality, and reduction of clinical symptoms, and may enable resumption of daily life activities. This case series retrospectively evaluated five aPAP pati...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.